Gene and Cell Therapy – Multimedia

How can you successfully scale your cell and gene therapy fill/finish process to minimize manual involvement, reduce the specialized training required, and deliver high-quality, high-value products, efficiently?

This whitepaper highlights essential factors to consider for the successful manufacturing of gene and cell therapies.

Vaccines, cell and gene therapy products must be certified as mycoplasma-free to meet regulatory requirements. Hence, mycoplasma contamination testing is a vital step in the biologics manufacturing process.

This handbook offers a practical guide to end-to-end GCT workflows, featuring tips, tricks and solutions to support a variety of high-throughput applications.

This episode explores revolutionizing drug discovery with genomic screening.

In this episode we discuss environmental monitoring, regulations, and introduce the Applied Biosystems MicroSEQ™ Rapid microbial ID system.

Adeno-associated viral vector (AAV) has become a preferred gene therapy delivery modality; however, AAV manufacturing is not without its challenges, whether that is using crude samples, a lack of standardized methods or incompatible techniques.

Despite the success of AAV for gene therapies and vaccines, many challenges still exist within AAV manufacturing. To ensure the safety and efficacy of a therapeutic, it is crucial to accurately determine the percentage of capsids that carry the gene of interest.

A scalable and robust solution for all stages of the gene therapy workflow to meet regulatory standards is essential, however, as the field is more recent, liquid media is the common format even though it can be more expensive and have a shorter shelf life.

Cell and gene therapies and regenerative medicines (CGT&RMs) offer remarkable biotherapeutic promise. However, developing and manufacturing CGT&RMs is no easy task, particularly when choosing how and where to deliver the production of a therapeutic.